title: [Bone anabolic treatment with Teriparatide].
abstract: The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide reduces vertebral fracture risk by 65 % and non-vertebral by 50 %. Its efficacy is higher as bisphosphonates to prevent corcicosteroid-induced osteoporosis. Teriparatide may also have a direct effect on bone pain. Teriparatide may be initiating immediately after an anticatabolic agent. However, it is not recommended to associate both treatments. At the end of teripatide treatment, an anticatabolic agent may be given. According to cost-effectiveness studies, Teriparatide should be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.
authors.affiliation: Service de Médecine Interne et Centre des Maladies Osseuses, CHUV, Lausanne. olivier.lamy@chuv.ch
authors.forename: Olivier
authors.initials: O
authors.lastname: Lamy
mesh_terms: D045930:Anabolic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D050071:Bone Density Conservation Agents; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*; D019379:Teriparatide / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D045930:Anabolic Agents; D050071:Bone Density Conservation Agents; D019379:Teriparatide